QUI TAM - QUI WHAT? Perspectives From Experienced Government Counsel,

Slides:



Advertisements
Similar presentations
Physicians Regulatory Insurance Program Presenter: Jay Lynch President Presenter: Jay Lynch President.
Advertisements

A GIA is a contract between a surety company and a contractor (or subcontractor)/principal. A GIA is a standard, typical document in the construction.
Wireless Password: © COPYRIGHT DICKSTEIN SHAPIRO LLP. ALL RIGHTS RESERVED. July 23, 2013 Dave Nadler The Next Wave: The Expansion of.
NC State University Office of General Counsel April 2010.
The Deficit Reduction Act, Deficit Reduction Act of 2005 In the Deficit Reduction Act of 2005 (DRA) Congress, for the first time, has mandated healthcare.
Our Goals Today To help you feel comfortable with asking questions.
State False Claims Acts How States Can Recover Stolen Money Jim Moorman, TAF Roderick Chen, OIG-HHS.
Hill Country CMHMR Center FRAUD & ABUSE Training August 2008.
North Carolina False Claims Act (WEBCAST) Presented by: The North Carolina Bar Association Tuesday, November 27, :00PM – 1:30PM.
What Every Physician Needs To Know About Fraud And Abuse Laws (But Is Afraid To Ask) Steven H. Cohen Cohen Law Group an affiliate of the Whistleblower.
© 2009 Cengage Learning. All Rights Reserved. Healthcare Fraud and Abuse.
UNIVERSITY OF PENNSYLVANIA Institutional Compliance Strategies at the University of Pennsylvania.
The False Claims Act and Its Impact on Federally Sponsored Research Jeff M. Seo J.D., LL.M. Director of Research Compliance Harvard Medical School.
BlueCare Tennessee and BlueCare, Independent Licensees of BlueCross BlueShield Association How the Deficit Reduction Act of 2005 Impacts BlueCare Tennessee.
1 PsychRights' Medicaid Fraud Initiative Against Psychiatric Drugging of Children & Youth James B. (Jim) Gottstein, Esq. Law Project for Psychiatric Rights.
2011 FRAUD & ABUSE UPDATE John Hellow Hooper, Lundy & Bookman, PC All views expressed in the seminar materials and.
False Claims in Construction, Update of NCHRP Study Topic
Sales & Marketing Compliance Training
Medicare Parts C and D Fraud, Waste, and Abuse Compliance Training
The United States False Claims Act Qui Tam Whistleblower Law Getnick & Getnick LLP | Counsellors At Law Rockefeller Center, 620 Fifth Avenue | New York,
FCA* for BEGINNERS *NEVADA FALSE CLAIMS ACT NRS et seq. L. TIMOTHY TERRY The Terry Law Firm, Ltd
April 26–28, 2004 Renaissance Orlando Resort at Seaworld Orlando, FL NCMA World Congress 2004 “Maximizing Value to Stakeholders…Contract Management in.
Regulatory Control of Providers Financial Relationships Civil False Claims The Act.
New HR Challenges in the Dynamic Environment of Legal Compliance By Teri J. Elkins.
Maryland State Bar Association Health Law Section Understanding Medicare Billing Issues: Anti-Markup Rules, Independent Diagnostic Testing Facility Rules,
Fraud, Waste & Abuse DEFICIT REDUCTION ACT OF 2005 Presented by: MARCH Vision Care, 2013.
DIVISION OF HEALTH SCIENCES OFFICE OF INSTITUTIONAL INTEGRITY Protecting Yourself and Your Practice.
Program Integrity. The Cost of Fraud, Waste, and Abuse Between July 2012 and January 2013, the North Carolina Division of Medical Assistance collected.
Federal False Claims Act and Qui Tam Actions Law Journal Press Webinar By: Joel M. Androphy, Sarah Frazier & Rachel Grier Berg & Androphy1.
Violations of the False Claims Act and The Importance of a Timely and Proper Response to Whistleblower Allegations Thomas J. Finn Paula Cruz Cedillo.
How to Make $4.1Billion in 12 Months: Healthcare Fraud and Abuse Enforcement Mark Bartlett Davis Wright Tremaine, LLP.
1 Medicaid Fraud and Abuse Investigations, Prosecutions and Compliance Strategies John T. Bentivoglio Combating Medicaid.
False Claims Act and Whistleblower Protections False Claims Act and Whistleblower Protections Genetic Disease Screening Program Employee Education and.
Recent False Claims Developments Robert J. Sherry K&L Gates May 2009.
Copyright© 2011 WeComply, Inc. All rights reserved. 9/6/2015 Whistleblowing.
THE BRODY SCHOOL OF MEDICINE NEW EMPLOYEE ORIENTATION COMMITMENT TO COMPLIANCE: INTRODUCTION TO THE BSOM COMPLIANCE PROGRAM Joan A. Kavuru, JD, RN Director.
© 2010 Cengage Learning. All Rights Reserved. May not be scanned, copied or duplicated, or posted to a publicly accessible website, in whole or in part.
COMPLIANCE PROGRAM. Agenda  Initial Scenarios  Review of General Compliance Information  Review UCP’s Compliance Program  Questions and Discussion.
False Claims Act in Brief Taxpayers Against Fraud.
Blue Cross of Idaho Medicare Advantage Provider Fraud, Waste and Abuse Training Fall 2009.
WHEN THE DEPARTMENT OF JUSTICE KNOCKS DOJ Enforcement Trends: What to Expect and How to Respond Jacqueline Arango Shareholder Akerman Senterfitt.
Sales and Marketing in the Pharmaceutical Industry: At the Vortex of the Perfect Legal Storm Paul E. Kalb, M.D., J.D. Princeton, N.J. - June 7, 2004.
Fraud and Abuse in Dentistry. Definition Fraud is the intentional perversion of truth in order to induce another to part with something of value, or surrender.
1 VIEW ON FRAUD AND ABUSE David E. Matyas Epstein Becker & Green Washington, DC.
STATE OF ARIZONA BOARD OF CHIROPRACTIC EXAMINERS Mission Statement The mission of the Board of Chiropractic Examiners is to protect the health, welfare,
1 United States Commercial Law Seminar Masaryk University April 11-21, 2011 Lecture Six: Internal investigations, Special Committees, and directorduties.
Welcome….!!! CORPORATE COMPLIANCE PROGRAM Presented by The Office of Corporate Integrity 1.
1 Restrictions on the Use of Federal Assistance Funds for Lobbying Federal Assistance Law Division U.S. Department of Commerce JAOM FMC May 2007.
National Medical Device Audioconference: How the Recent Landmark $311 Million Device Settlements Will Change Industry Practices Insights Into Federal Investigations.
Welcome General Compliance Training.  To inform you who to contact to ask questions  To let you know that you are responsible to disclose  To share.
1 Pharmacy Management and Cost-Containment: Pharmaceutical Fraud Investigations, Prosecutions and Compliance Strategies John T. Bentivoglio
Gerald M. Burke Assistant United States Attorney 9 Executive Drive Fairview Heights, Illinois (618) Fax (618)
Toll Free (800) Contact Information A NATIONWIDE LEADER IN SUCCESSFUL QUI TAM CASES WARREN | BENSON LAW GROUP has prosecuted Qui Tam cases in more.
The ABC’s and FAQ’s of Exclusion Monitoring Not so easy as 1,2,3… ProviderTrust, Inc. All rights Reserved. Copyrighted
The Growing Role of HHS-IG/DOJ, & Whistleblowers, In Drug Marketing Policy John F. Kamp August 25, 2005.
GOVERNMENT LAWYER’S REPRESENTATION OF GOVERNMENT EMPLOYEES Craig E. Leen City Attorney City of Coral Gables *** With special thanks to Yaneris Figueroa,
© 2016 McGraw-Hill Education. All rights reserved. Ch 8 Privacy, Security and Fraud.
FRAUD, WASTE & ABUSE WHAT YOU NEED TO KNOW STCHCN – 12/7/2015.
Compliance and Enforcement Roundtable Discussion
Action Items: Monitoring Off-Label Promotion Do’s and Don’t’s
Thomas J. Finn Paula Cruz Cedillo
Fraud Waste and Abuse Company Training.
FRAUD, WASTE, & ABUSE (FWA) 2012
PHARMA AUDIOCONFERENCE An Analysis of the HHS OIG Draft Compliance Program Guidance for the Pharmaceutical Industry Overview of Draft CPG Michael P.
FCA Enforcement: United States Department of Justice
15th Annual ABA Washington Health Law Summit December 5, 2017
Northern Michigan Regional Entity Region 2
COMPLIANCE PROGRAM.
Brussels, June 6, 2007 Paul E. Kalb, M.D., J.D.
Introduction to Qui Tam Litigation
Presentation transcript:

QUI TAM - QUI WHAT? Perspectives From Experienced Government Counsel, Relator’s Counsel & Defense Counsel 17th Annual FLABOTA Convention Friday, July 18th, 2014 The Breakers Palm Beach, Florida

SPEAKERS Government Counsel Relator’s Counsel Defense Counsel Jeffrey W. Dickstein, Esq. Assistant United States Attorney, United States Attorney’s Office for the Southern District of Florida (jeffrey.dickstein@usdoj.gov) Relator’s Counsel Marc S. Raspanti, Esq. Partner, Pietragallo Gordon Alfano Bosick & Raspanti, LLP in Philadelphia, PA (www.Pietragallo.com / www.FalseClaimsAct.com / www.FraudWhistleblowersBlog.com) Defense Counsel Meredith S. Auten, Esq. Partner, Morgan Lewis & Bockius, LLP in Philadelphia, PA (www.MorganLewis.com)

THE FALSE CLAIMS ACT OVERVIEW 1863 - 2014 Enacted during the Civil War by Abraham Lincoln to combat Defense Contractor fraud Also called the Qui Tam Statute, the Whistleblower Law or the “Lincoln Law” Strengthened in 1986 during the Cold War Expansive reach – all goods/services provided with any federal funds, now heavily focused on fraud in Healthcare programs Vibrant Future – Recently amended substantially by Congress Can affect any institution, entity or individuals doing business directly or indirectly with the government

THE FALSE CLAIMS ACT False Claims Acts apply to all types of goods, services and Government contracting, and have been particularly effective in combating Healthcare (Medicare and Medicaid) Fraud Pharmaceutical Fraud Financial Industry Fraud Defense Contracting Fraud Energy (Oil and Gas) Contracting Fraud Iraq Reconstruction Fraud Environmental Fraud Disaster Relief Fraud Construction and Procurement Fraud Research Fraud

STATE FALSE CLAIMS ACT 29 states currently have their own False Claims Act The Florida FCA was passed in 1994 and amended in 2007 Morgan Lewis partner Bobby Brochin was a drafter

29 States now have their own FCAs STATE FALSE CLAIMS ACT 29 States now have their own FCAs California Colorado Connecticut Delaware Florida Georgia Hawaii Illinois Indiana Iowa Louisiana Maryland Massachusetts Michigan Minnesota Montana Nevada New Hampshire New Jersey New Mexico New York North Carolina Oklahoma Rhode Island Tennessee Texas Virginia Washington Wisconsin

MUNICIPALITY FALSE CLAIMS ACT The following municipalities have their own False Claims Acts: Chicago New York City District of Columbia Philadelphia Allegheny County, PA

FEDERAL FALSE CLAIMS ACT Qui tam cases produced $39 billion in settlements - hundreds of millions to over $1 billion in some cases Examples of top civil recoveries: GlaxoSmithKline - $2 billion Johnson & Johnson - $1.7 billion Pfizer - $1 billion Bank of America - $1 billion Tenet Health - $900 million Abbott - $800 million Home America Mortgage - $320 million

FEDERAL FALSE CLAIMS ACT What it does NOT cover: FCA does NOT cover tax fraud New IRS Whistleblower Provision 26 U.S.C. § 7623 New SEC Whistleblower Program 15 U.S.C. 78a et seq.

FEDERAL FALSE CLAIMS ACT PROHIBITED CONDUCT FCA prohibits: Knowing submission or causing submission of false or fraudulent claims for payment Knowing submission or causing submission of false or fraudulently records in support of a false claim Conspiracy to submit a false claim Submission of false records to reduce money owed to the United States 31 U.S.C. § 3729

FEDERAL FALSE CLAIMS ACT PROHIBITED CONDUCT Not limited to classic fraud “Knowing” falsity broadly defined Actual knowledge Reckless disregard / deliberate ignorance of the truth or falsity of the information – “ostrich with its head in the sand” Regulatory / contractual violations can be recast as knowing falsity

WHAT IS A CLAIM UNDER FCA? Any request or demand, whether under a contract or otherwise, for money or property which is made to a contractor, grantee, or other recipient if the U.S. provides or reimburses any portion of the money or property Examples of Claims Under the Act: Direct requests for payment Indirect requests for payment Obligations owed to the Government Bids Loan applications Grant documents Cost reports

FEDERAL FALSE CLAIMS ACT What Defendants can owe if held liable: Defendant liable for mandatory treble damages sustained by the Government Defendant also liable for penalty of between $5,500 and $11,000 per claim for each false claim to the Government Defendant liable for attorney’s fees and litigation costs Joint and several liability with no right of contribution or indemnity

FEDERAL FALSE CLAIMS ACT Who can be a “relator?” A relator can be any “person,” including individuals, entities, and companies

QUI TAM LITIGATION How will investigation generally proceed? Civil Investigative Demands Inspector General Subpoenas Search Warrants Grand Jury Interviews – voluntary Criminal HIPAA Subpoenas

HOT BUTTON SECTIONS OF LAW First to File Bar - 31 U.S.C. § 3730(b)(5) Public Disclosure Bar - 31 U.S.C. § 3730(e)(4)(A) Original Source - 31 U.S.C. § 3730(e)(4)(B) Fair, Adequate & Reasonable - 31 U.S.C. § 3730(c)(2)(B) Relator Share Award - 31 U.S.C. § 3730(d)(1) Attorney Fees Award - 31 U.S.C. § 3730(d)(1) Anti-Retaliation Provision - 31 U.S.C. § 3730(h)

FEDERAL FALSE CLAIMS ACT Attorney’s Fees and Costs If found liable, Defendant must pay the Relator’s reasonable attorney’s fees and costs Attorney’s fees and costs are in addition to Relator’s share of the recovery by the Government

FEDERAL FALSE CLAIMS ACT Whistleblower Protection – 3730(h) FCA protects any employee, contractor or agent discriminated against because of lawful acts done in furtherance of an FCA action Entitled to “all relief necessary to be made whole,” including two times back pay, special damages, attorney’s fees and costs

FEDERAL FCA ANTI-RETALIATION PROVISION 31 U.S.C. 3730(h)(1) Relief From Retaliatory Actions — (1) In general — Any employee, contractor, or agent shall be entitled to all relief necessary to make that employee, contractor, or agent whole, if that employee, contractor, or agent is discharged, demoted, suspended, threatened, harassed, or in any other manner discriminated against in the terms and conditions of employment because of lawful acts done by the employee, contractor, agent or associated others in furtherance of other efforts to stop 1 or more violations of this subchapter

RELATOR’S PRIVATE CAUSES OF ACTION Under Common Law Intentional torts Breach of Contract State Statutes New Jersey Conscientious Employee Protection Act Watch preemption issues

FEDERAL FALSE CLAIMS ACT Important Legal Issues 6-year statute of limitations, but can be extended to 10 years in certain cases Only the Relator who is the “First-to-File” eligible to share in the recovery

QUI TAM LITIGATION Whistleblower – a.k.a. “Relator” Files in the name of the Government Complaint filed under seal United States has 60 days to investigate and decide whether to intervene or not – declination is 75% - 80% of cases Decline and allow the private person to pursue the case on their own File a notice of non-intervention at this time Relator shares in recovery (15% - 30%) Relator recoveries are currently higher in DOJ-intervened cases

QUI TAM LITIGATION Relator and his information: Employee or ex-employee of defendant May have been involved in fraud to limited extent May be Government employee Cannot be a member of the Armed Services for actions arising out of military service Second qui tam on same facts is barred Public disclosure bar unless “original source” Now government discretion to oppose dismissal

QUI TAM LITIGATION Intervention: Government may elect to intervene or decline In some or all of allegations Can file an amended complaint / common law causes of action Seal is lifted If Government declines, it still remains real party in interest Relators may pursue case on behalf of the government unless government moves to dismiss

QUI TAM LITIGATION Relators’ shares: If Government intervenes, 15% - 25% plus attorney fees and costs If Government declines, 25% - 30% plus attorney fees and costs Awards reduced for relators who planned and initiated fraud; no recovery if criminally convicted of fraud

THE MODERN FEDERAL FCA Two separate Causes of Action Fraud Cause of Action – Whistleblower essentially shares with the Government 31 U.S.C. § 3730(h) allegation – Relator’s Cause of Action only

HEALTH CARE FRAUD Since the 1986 amendments to the federal FCA, the federal Government has recovered over $30 Billion from False Claims Act cases. More than 67% of qui tam cases in the last decade have been health care fraud qui tam cases. Typical health care defendants: pharmaceutical companies; medical device companies; hospitals; durable medical equipment; physicians; medical suppliers

TYPICAL QUI TAM HEALTH CARE FRAUD WHISTLEBLOWERS Pharma Sales Reps & Managers Medical Device Sales Reps Any Sales Reps Medical Directors Physicians Hospital Executives Quality Control Personnel Pharmacists Nurses Accountants Contractors Compliance Officers Counsel

TYPICAL HEALTH CARE FRAUD ALLEGATIONS Drugs – (off label marketing; kickbacks; inflated pricing; PRM fraud) Upcoding Excessive or unnecessary medical / diagnostic tests being performed on patients No health care services actually provided to the patient Kickback to illegally induce physician referrals All types of hospital based fraud Stark Violations Ghost patients billed Quality of health care services provided Overcharging Government health programs for DME, services Unlawful sales and promotion Research grant fraud

TYPICAL HEALTH CARE FRAUD ALLEGATIONS Regulatory violations: any will do? Conflicts of interest, violations of industry codes of ethics, state laws Various certifications of compliance

TYPICAL ALLEGATIONS AGAINST MEDICAL DEVICE AND DRUG MANUFACTURERS Cozy financial relationships between and among owners; Aggressive “off-label” marketing practices; Inappropriate marketing efforts; Unapproved or adulterated devices and drugs; Safety issues; Industry sponsoring and paying for research; Clinical trial issues; FDA indications; Direct consumer advertising issues; Shortcuts in quality of care; KICKBACKS…KICKBACKS…KICKBACKS

ENFORCEMENT LANDSCAPE Skewed industry focus on one industry sector: health care Other industries ripe for focus: financial services, technology, retail, defense contractors, energy, educational institutions Financial Fraud Enforcement Task Force Procurement Fraud Task Force Well over 1,000 qui tams currently under seal – majority are health care, but many financial institution defense contractors as well

ENFORCEMENT LANDSCAPE Most civil and criminal cases have been and will continue to be driven by qui tam plaintiffs and their counsel 3.8 billion recovered in 2013 752 qui tam filed in 2013- 2.9 million in recoveries 2.6 billion of 3.8 billion recovered from health care matters Much better coordination between Feds and many State AGs High Level of coordination between civil and criminal prosecutors Over 160 federal qui tam actions spread across many judicial districts against medical device and pharmaceutical manufacturers $385 million to whistleblowers in 2013

ENFORCEMENT LANDSCAPE Judicial impatience with length of DOJ investigations under seal in some jurisdictions – internal DOJ 9-month rule Consortiums of relator counsel banding together Professional whistleblowers More sophisticated attorneys, more aggressive, more willing to fight at all levels More cases going through discovery to the courthouse steps

HEALTH CARE FRAUD INVESTIGATIONS: UNIQUE CHALLENGES Complex regulatory framework Complex payment and reimbursement system Medicare, 49 Medicaid programs, other health care programs – SCHIP, TRICARE, FEHB, VHA, HIS Centers for Medicare and Medicaid Services, i.e. CMS/OIG/FDA CMS policies and the FCA law don’t always interact Knowing where to find the answer is not always easy

HEALTH CARE FRAUD INVESTIGATIONS: UNIQUE ASPECTS Health care first or second largest expenditure of funds in the country Relators / whistleblowers are everywhere from the lunch room to the board room Nature of health care is “interaction” with all aspects of society Lots of claims / millions of submissions / billions of dollars Many disgruntled, downsized, displaced or demoted employees Exclusion from the Medicare and Medicaid program is a powerful deterrent

KEY STATUTES Federal False Claims Act – 31 USC 3729 et seq. False Claims Act Anti-Retaliation Provisions – 31 USC 3730(h) 29 State False Claims Acts Anti-Kickback Statutes – State and Federal The Stark Law, 42 USC §1395nn FERA (2009) and PPACA (2010) amendments

DEFENSE PERSPECTIVES Well-developed body of case law favorable to defense – significant battlegrounds Scienter standard – negligent, innocent mistakes not enough; ambiguous regulations not rise to level of knowing violations Public disclosure and first-to-file bar – series of defense-favorable recent decisions to prevent parasitic suit Proper measure of damages – good recent decisions that proper measure damages takes into account benefit government received Penalties – can violate 8th Amendment; maybe not per claims, but per act Enforceability of releases – more courts enforcing Rule 9(b) requirement to plead fraud with particularity

DEFENSE PERSPECTIVES Goal #1: manage company’s credibility in all communications and strategic actions from first call to government forward Define strategy early Determine what to fight about substantively on legal issues: not on document production unless abuse through CID process Goal is always DOJ declination as well as relator dismissal

DEFENSE PERSPECTIVES Recent FCA amendments confirm proactive strategies are necessary before intervention CIDS and information sharing with relators and states may require defense interaction with the court Robust compliance programs remain the best defense Encourage employees, agents and contractors to use internal channels to address concerns Investigate all of those calls

QUI TAM LITIGATION – IT’S COMPLICATED! Intricacies of Federal Programs/Agencies Complexity of Liability and/or Damages Creates Difficulties Relationships/Reputation with Government and Other Relator’s Counsel Qui Tam Litigation: Relator + Government + Defendant = Complicated³

COMPLEXITY CREATES OPPORTUNITIES The process of a qui tam lawsuit: A potential whistleblower’s first consideration False Claims Act lawyer’s screening of the Relator’s evidence Special aspects in drafting the FCA Complaint and statutory disclosures Filing the case and presenting the matter to the Government Company’s response to an investigation Government’s determination of whether to join the case Relator’s involvement during the seal period and beyond Settlement and/or litigation phase of the action

QUESTIONS